Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Azixa

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Pharmacophore Modeling, Docking and Molecular Dynamics Studies on Caspase-3 Activators Binding at β-Tubulin Site.
Induction of apoptosis by the activation of caspase 3 makes it a promising target for designing anticancer drugs hence an… 
2015
2015
Identification of imidazoquinoline derivatives as potent antiglioma agents.
Glioblastoma Multiforme (GBM) is a highly fatal disease and new chemotherapeutic agents are desperately needed to treat GBM… 
2015
2015
Phase II Study of Verubulin (Azixa, MPC-6827) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma Multiforme Patients: Incomplete Report on Safety, Tolerability and Responses (P3…
OBJECTIVE: To establish safety, tolerability and efficacy of Azixa when combined with standard of care therapy (SOC) (RT/TMZ) in… 
2014
2014
Effects of the Tumor‐Vasculature‐Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels
Two analogues of the discontinued tumor vascular‐disrupting agent verubulin (Azixa®, MPC‐6827, 1) featuring benzo‐1,4‐dioxan‐6‐yl… 
2010
2010
Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2010
2010
Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring.
As a continuation of our efforts to discover and develop apoptosis inducing N-methyl-4-(4-methoxyanilino)quinazolines as novel… 
  • table 2
  • table 1
2010
2010
Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.
8531 Background: MPC-6827 (Azixa) is a microtubule destabilizing agent. This study was designed to establish the safety and… 
2010
2010
A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.
2095 Background: MPC-6827 (Azixa; 4-arylaminoquinazoline) is a microtubule destabilizing agent that achieves high brain… 
2010
2010
Molecular Medicine in Practice Phase I Clinical Trial of MPC-6827 ( Azixa ) , a Microtubule Destabilizing Agent , in Patients with Advanced Cancer
MPC-6827 (Azixa) is a small-moleculemicrotubule-destabilizing agent that binds to the same (or nearby) sites on b-tubulin as… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2009
2009
Abstract #3606: Azixa, a microtubule formation inhibitor in solid tumors: results of a phase 1 clinical trial
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Purpose: Azixa\#8482; (MPC-6827) (4-arylaminoquinazolines) is a small molecule… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE